In this episode of Trade Compliance Brief - Export Control and Sanctions Insights, we dive into the recent Bureau of Industry and Security (BIS) settlement with Texas-based neuroscience company Plexon, Inc.
We unpack how eight shipments of neural recording data acquisition systems routed through an Asian distributor resulted in a massive $1.7 million suspended penalty and a suspended five-year denial of export privileges. We also explore the rising regulatory scrutiny surrounding emerging technologies like Brain-Computer Interfaces (BCI) and the strict liability companies face when end-users end up on the BIS Entity List.
Key Takeaways in this Episode:
The Distributor Blind Spot: Why utilizing regional distributors does not shield manufacturers from EAR violations when the final end-user is restricted.
Entity List Enforcement: An analysis of the Academy of Military Medical Sciences (AMMS) designation and the strict licensing requirements for entities supporting foreign military end-uses.
Emerging Tech Controls: How the Export Control Reform Act of 2018 is actively shaping the landscape for biotechnology and Brain-Computer Interface (BCI) exports.
Compliance Remediation: A look at the stringent external audit and mandatory global training requirements BIS imposes to suspend multi-million dollar penalties.
Podden och tillhörande omslagsbild på den här sidan tillhör
Pete. Innehållet i podden är skapat av Pete och inte av,
eller tillsammans med, Poddtoppen.
